Sihuan Pharmaceutical Profit Doubles, Appoints New Director to Bolster Drug Pipeline

Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) reported a 119% surge in profit for the first half of 2026 and announced a key board appointment, underscoring the success of its "dual-driver" growth strategy focused on medical aesthetics and innovative drugs.

Dual-Driver Strategy Delivers Strong Results

In its interim results announcement, the Hong Kong-listed company disclosed that profit attributable to its owners reached ¥225 million for the period. Total revenue saw a modest increase of 1.3% year-over-year to ¥1.161 billion, with growth concentrated in its two core business areas.

The performance breakdown highlights the strategy's effectiveness:

• Medical Aesthetics: This segment's revenue grew by approximately 18.5% to ¥693 million. Growth was attributed to the stable performance of its core botulinum toxin product, Letybo®, and rising sales from its portfolio of regenerative and functional aesthetic products.
• Innovative Drugs & Other Pharmaceuticals: This division experienced explosive growth, with revenue soaring 349.1% year-over-year to ¥261 million. The company stated that the successful commercialization of several recently approved products helped the segment swing to a net profit, compared to a net loss in the same period last year.

Ad

Board Appointment Strengthens Innovation Focus

In a separate corporate governance update, Sihuan announced the appointment of Che Yuxuan as a non-executive director and a member of the Board's Risk Management Committee, effective August 26, 2026.

Che holds a bachelor's degree in biology from the University of Washington and has prior experience as a data science researcher at Massachusetts General Hospital and in marketing and sales with Sanofi Pasteur. The company noted his extensive background in biomedical research, commercialization, and strategic management.

Market observers believe Che's expertise aligns closely with Sihuan's strategic push into innovative pharmaceuticals. His appointment is expected to enhance the board's decision-making capabilities and resource integration for the company's drug pipeline, which is a critical component of its long-term growth plan.